DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR INSULIN ASPART RECOMBINANT
» See Plans and Pricing
505(b)(2) Clinical Trials for Insulin Aspart Recombinant
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Formulation | NCT01487811 | Comparison of Two Biphasic Insulin Aspart 30 Formulations (Current and New Formulation) in Healthy Volunteers | Completed | Novo Nordisk A/S | Phase 1 | 2005-05-01 | This trial is conducted in the United states of America (USA). The aim of this trial is to compare two formulations of biphasic insulin aspart 30 in healthy volunteers. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Insulin Aspart Recombinant
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00046150 | 12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes. | Completed | Sanofi | Phase 3 | 2002-05-01 | The purpose of this study is to compare the safety of HMR 1964 and insulin aspart when used in external pumps with respect to catheter occlusions, GHb assessment, insulin doses, blood glucose parameters, hypoglycemic episodes, unexplained hyperglycemia, adverse events, laboratory data, and vital signs. |
| NCT00065130 | Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes | Completed | Novo Nordisk A/S | Phase 3 | 2000-04-01 | This trial is conducted in the United States of America (USA). The purpose of this study is to test whether NovoLog (insulin aspart) is a safe and at least as effective alternative to regular human insulin for the control of blood glucose after meals in women who develop diabetes during pregnancy. |
| NCT00071448 | Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population | Completed | Novo Nordisk A/S | Phase 3 | 2002-06-01 | This trial is conducted in the United States of America (USA). The aim of this trial is to to determine whether insulin aspart can be used effectively and safely in paediatric patients. |
| NCT00082407 | Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin | Completed | Eli Lilly and Company | Phase 3 | 2003-11-01 | This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as measured by hemoglobin A1c (HbA1c). |
| NCT00082407 | Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin | Completed | AstraZeneca | Phase 3 | 2003-11-01 | This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as measured by hemoglobin A1c (HbA1c). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Insulin Aspart Recombinant
Clinical Trial Locations for Insulin Aspart Recombinant
Trials by Country
Clinical Trial Progress for Insulin Aspart Recombinant
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Insulin Aspart Recombinant
Sponsor Name
